In October, Personalized Stem Cells (PSC) was a primary sponsor of an event put on by the Arthritis Foundation in Los Angeles, California.
Personalized Stem Cells Co-Founder and Chief Scientific Officer, Dr. Bob Harman, will be a panelist in a discussion about Optimizing Cell Product Development and Delivery to Patients at the upcoming CTTACC conference.
The FDA has the authority to regulate stem cell therapies in the United States. In July of 2019, PSC announced the FDA approval of their IND to treat osteoarthritis with autologous adipose-derived stem cell therapy through clinical trials.
Autologous Adipose-Derived Stem Cell Therapy is a medical therapy used to treat orthopedic conditions.